GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Current Ratio

Infant Bacterial Therapeutics AB (OSTO:IBT B) Current Ratio : 4.80 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Infant Bacterial Therapeutics AB's current ratio for the quarter that ended in Jun. 2024 was 4.80.

Infant Bacterial Therapeutics AB has a current ratio of 4.80. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's Current Ratio or its related term are showing as below:

OSTO:IBT B' s Current Ratio Range Over the Past 10 Years
Min: 2.41   Med: 23.73   Max: 109.37
Current: 4.8

During the past 10 years, Infant Bacterial Therapeutics AB's highest Current Ratio was 109.37. The lowest was 2.41. And the median was 23.73.

OSTO:IBT B's Current Ratio is ranked better than
58.75% of 1508 companies
in the Biotechnology industry
Industry Median: 3.75 vs OSTO:IBT B: 4.80

Infant Bacterial Therapeutics AB Current Ratio Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Current Ratio Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.15 43.10 30.03 18.93 7.40

Infant Bacterial Therapeutics AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.43 9.26 7.40 4.74 4.80

Competitive Comparison of Infant Bacterial Therapeutics AB's Current Ratio

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Current Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Current Ratio falls into.



Infant Bacterial Therapeutics AB Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Infant Bacterial Therapeutics AB's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=341.563/46.18
=7.40

Infant Bacterial Therapeutics AB's Current Ratio for the quarter that ended in Jun. 2024 is calculated as

Current Ratio (Q: Jun. 2024 )=Total Current Assets (Q: Jun. 2024 )/Total Current Liabilities (Q: Jun. 2024 )
=287.08/59.766
=4.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB  (OSTO:IBT B) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Infant Bacterial Therapeutics AB Current Ratio Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines